Literature DB >> 29300437

Real-Life Peak and Trough Dabigatran Plasma Measurements over Time in Hospitalized Geriatric Patients with Atrial Fibrillation.

E Chaussade1, O Hanon, C Boully, F Labourée, L Caillard, G Gerotziafas, J-S Vidal, I Elalamy.   

Abstract

BACKGROUND: Few geriatric patients were included in studies on direct oral anticoagulants and data on dabigatran concentration and safety are needed in this population. Our objectives were to evaluate peak and trough dabigatran plasma concentrations over time in a geriatric population and to identify factors associated with dabigatran plasma concentrations and to assess the relationship with bleeding events.
METHODS: Peak and trough dabigatran plasma concentration were performed 4,8,15,30,45 days after inception of dabigatran treatment in 68 consecutive patients ≥75 years old hospitalized in a geriatric hospital with atrial fibrillation. Bleeding events were monitored for 1 year.
RESULTS: Mean age was 85.8(5.1) years old and 76.5% were women. Overall, 541 dabigatran plasma measurements (270 peak, 271 trough) were performed. Mean dabigatran concentrations of the 5 sequential measurements ranged 106-146ng/mL for peak and 66-84ng/mL for trough. Renal failure was associated with high peak and trough dabigatran concentration. Inter- and intra-individual coefficients of variation were 59.5% and 44.7% for peak and 74.5% and 44.6% for trough. Participants in the lower two tertiles of dabigatran concentration at day 8 (D8) remained below the 90th percentile (243.9ng/ml) on the next measurements. Bleeding events were associated with high trough dabigatran concentrations. Trough dabigatran concentration at D8>243.9ng/mL significantly predicted bleeding.
CONCLUSION: In this geriatric population, renal function and low albumin were associated with dabigatran concentrations. Despite large variability, participants in the lower two tertiles of dabigatran concentration at D8 remained below the 90th percentile on the following measurements. D8 dabigatran trough concentration≥243.9ng/mL identified patients at risk of bleeding.

Entities:  

Keywords:  80 and over; Anticoagulants; aged; antithrombins; atrial fibrillation

Mesh:

Substances:

Year:  2018        PMID: 29300437     DOI: 10.1007/s12603-017-0982-4

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


  37 in total

Review 1.  Drug therapy in the elderly.

Authors:  Klaus Turnheim
Journal:  Exp Gerontol       Date:  2004 Nov-Dec       Impact factor: 4.032

2.  New anticoagulant drugs among elderly patients is caution necessary?: Comment on "The use of dabigatran in elderly patients".

Authors:  Jeremy M Jacobs; Jochanan Stessman
Journal:  Arch Intern Med       Date:  2011-07-25

3.  Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.

Authors:  Joachim Stangier; Karin Rathgen; Hildegard Stähle; Dago Mazur
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

4.  Doctors' beliefs on the use of antithrombotic therapy in atrial fibrillation: identifying barriers to stroke prevention.

Authors:  G M Peterson; K Boom; S L Jackson; J H Vial
Journal:  Intern Med J       Date:  2002 Jan-Feb       Impact factor: 2.048

5.  The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

Authors:  Paul A Reilly; Thorsten Lehr; Sebastian Haertter; Stuart J Connolly; Salim Yusuf; John W Eikelboom; Michael D Ezekowitz; Gerhard Nehmiz; Susan Wang; Lars Wallentin
Journal:  J Am Coll Cardiol       Date:  2013-09-27       Impact factor: 24.094

6.  Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.

Authors:  Partha Sardar; Saurav Chatterjee; Carl J Lavie; Jay S Giri; Joydeep Ghosh; Debabrata Mukherjee; Gregory Y H Lip
Journal:  Int J Cardiol       Date:  2014-11-13       Impact factor: 4.164

7.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

Review 8.  Drug therapy in the elderly.

Authors:  Rudolf E Noble
Journal:  Metabolism       Date:  2003-10       Impact factor: 8.694

9.  Validation of a combined comorbidity index.

Authors:  M Charlson; T P Szatrowski; J Peterson; J Gold
Journal:  J Clin Epidemiol       Date:  1994-11       Impact factor: 6.437

10.  Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people.

Authors:  Olivier Hanon; Patrick Assayag; Joel Belmin; Jean Philippe Collet; Jean Paul Emeriau; Laurent Fauchier; Françoise Forette; Patrick Friocourt; Armelle Gentric; Christophe Leclercq; Michel Komajda; Jean Yves Le Heuzey
Journal:  Arch Cardiovasc Dis       Date:  2013-05-29       Impact factor: 2.340

View more
  2 in total

1.  Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines.

Authors:  Anne-Laure Sennesael; Nadtha Panin; Christelle Vancraeynest; Lionel Pochet; Anne Spinewine; Vincent Haufroid; Laure Elens
Journal:  Sci Rep       Date:  2018-07-12       Impact factor: 4.379

2.  Changing the Approach to Anticoagulant Therapy in Older Patients with Multimorbidity Using a Precision Medicine Approach.

Authors:  Angela Koverech; Valeriano Soldati; Vittoria Polidori; Leda Marina Pomes; Luana Lionetto; Matilde Capi; Andrea Negro; Maurizio Simmaco; Paolo Martelletti
Journal:  Int J Environ Res Public Health       Date:  2018-08-02       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.